Palvella Therapeutics, Inc. (PVLA) vs Sarepta Therapeutics, Inc. (SRPT)
A side-by-side comparison of Palvella Therapeutics, Inc. and Sarepta Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
PVLA
Palvella Therapeutics, Inc.
$128.00HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
SRPT
Sarepta Therapeutics, Inc.
$17.31HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — PVLA vs SRPT
growth of $100 · dividends reinvested · last 2yPVLA +677.4% (+178.8%/yr)SRPT -86.1% (-62.7%/yr)PVLA compounded faster over this window
Log scale — wide-divergence pair
PVLA SRPT
PVLA vs SRPT: by the numbers
- •PVLA is the larger company ($1.84B vs $1.83B market cap).
- •Both run net losses; PVLA's is the smaller (0.00% vs -6.93% net margin).
Metrics side by side
Valuation
| Metric | PVLA | SRPT |
|---|---|---|
| Forward P/E | N/A | 5.38 |
| P/S ratio | N/A | 0.93 |
| P/B ratio | 8.47 | 1.20 |
Profitability
| Metric | PVLA | SRPT |
|---|---|---|
| Gross margin | 0.00% | 58.56% |
| Operating margin | 0.00% | -29.92% |
| Net margin | 0.00% | -6.93% |
| ROE | -28.45% | -8.95% |
| ROIC | -23.90% | -5.33% |
Growth (annualized)
| Metric | PVLA | SRPT |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 26.90% |
| Total return CAGR (5Y) | N/A | -28.74% |
Go deeper
Dig into the metrics
Palvella Therapeutics ROESarepta Therapeutics ROEPalvella Therapeutics operating marginSarepta Therapeutics operating marginPalvella Therapeutics revenue growthSarepta Therapeutics revenue growthPalvella Therapeutics free cash flowSarepta Therapeutics free cash flow
Palvella Therapeutics & Sarepta Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.